Evidence map›Paper›PMID 24426785›Full record

ArticleStem cells and cloning : advances and applications2013

Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives.

Senthilkumar Preethy, Sudhakar John, Jegatheesan Saravana Ganesh, Thangavelu Srinivasan, Hiroshi Terunuma, Masaru Iwasaki, Samuel J Abraham

Open access · goldAbstract read
In one paragraph

Article in Stem cells and cloning : advances and applications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Informatics Approaches for Harmonized Intelligent Integration of Stem Cell Research.Stem cells and cloning : advances and applications · 2020
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Senthilkumar PreethyNichi-In Centre for Regenerative Medicine, Chennai, India ; Hope Foundation Trust, Chennai, India.
Sudhakar JohnNichi-In Centre for Regenerative Medicine, Chennai, India.
Jegatheesan Saravana GaneshNichi-In Centre for Regenerative Medicine, Chennai, India.
Thangavelu SrinivasanNichi-In Centre for Regenerative Medicine, Chennai, India.
Hiroshi TerunumaBiotherapy Institute of Japan, Tokyo.
Masaru IwasakiYamanashi University School of Medicine, Chuo, Japan.
Samuel J AbrahamNichi-In Centre for Regenerative Medicine, Chennai, India ; Yamanashi University School of Medicine, Chuo, Japan.
Institute for Stem Cell Biology and Regenerative Medicine · INUniversity of Yamanashi · JPBiotherapy Institute of Japan · JPHope Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among the various strategies providing a cure for illness, cell-based therapies have caught the attention of the world with the advent of the "stem cell" era. Our inherent understanding indicates that stem cells have been in existence since the birth of multicellular organisms. However, the formal discovery of stem cells in the last century, followed by their intricate and extensive analysis, has led to clinical and translational efforts with the aim of using them in the treatment of conditions which don't have a definitive therapeutic strategy, has fueled our interest and expectations. Technological advances in our ability to study their cellular components in depth, along with surface markers and other finer constituents, that were unknown until last century, have improved our understanding, leading to several novel applications. This has created a need to establish guidelines, and in that process, there are expressed understandings and views which describe cell therapy along lines similar to that of biologic products, drugs, and devices. However, the age-old wisdom of using cells as tools for curing illness should not be misled by recent knowledge, to make cell therapy using highly complex stem cells equal to factory-synthesized and reproducible chemical compounds, drugs, or devices. This article analyses the differences between these two entities from various perspectives.

Indexed as

cell transplantationdrugsregenerative medicinestem cells

Identifiers

PMID24426785
PMCPMC3850297
OpenAlexW1972679617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.